Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1972 1
1973 1
1977 1
1979 2
1980 1
1983 3
1984 2
1985 5
1986 3
1987 2
1989 2
1990 1
1991 1
1992 2
1995 2
1998 1
1999 1
2000 3
2001 1
2002 3
2003 5
2004 3
2005 1
2009 2
2010 1
2011 1
2012 3
2013 3
2014 1
2015 3
2016 2
2017 2
2018 2
2019 2
2020 2
2021 1
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Socinski MA, et al. J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547591 Clinical Trial.
RESULTS: On the basis of independent assessment, nab-PC demonstrated a significantly higher ORR than sb-PC (33% v 25%; response rate ratio, 1.313; 95% CI, 1.082 to 1.593; P = .005) and in patients with squamous histology (41% v 24%; response rate ratio, 1.680; 95% C …
RESULTS: On the basis of independent assessment, nab-PC demonstrated a significantly higher ORR than sb-PC (33% v 25%; response rate …
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Sequist LV, et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816960 Corrected and republished. Clinical Trial.
Hypercoagulability.
Hirsh J. Hirsh J. Semin Hematol. 1977 Oct;14(4):409-25. Semin Hematol. 1977. PMID: 72416 Review. No abstract available.
Medical device-induced thrombosis: what causes it and how can we prevent it?
Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Jaffer IH, et al. J Thromb Haemost. 2015 Jun;13 Suppl 1:S72-81. doi: 10.1111/jth.12961. J Thromb Haemost. 2015. PMID: 26149053 Free article. Review.
This study (i) examines the interface between devices and blood, (ii) reviews the pathogenesis of clotting on blood-contacting medical devices, (iii) describes contemporary methods to prevent thrombosis on blood-contacting medical devices, (iv) explains why some anticoagulants ar …
This study (i) examines the interface between devices and blood, (ii) reviews the pathogenesis of clotting on blood-contacting medical devic …
Management of patients with hereditary hypercoagulable disorders.
Kearon C, Crowther M, Hirsh J. Kearon C, et al. Annu Rev Med. 2000;51:169-85. doi: 10.1146/annurev.med.51.1.169. Annu Rev Med. 2000. PMID: 10774459 Review.
The inherited hypercoagulable states can be divided into those that are common and associated with a modest risk of thrombosis (i.e. factor V Leiden and G20210A prothrombin gene) and those that are uncommon but associated with a high risk of thrombosis. There is no convinc …
The inherited hypercoagulable states can be divided into those that are common and associated with a modest risk of thrombosis (i.e. factor …
Prophylaxis and therapy of venous thromboembolism.
Turpie AG, Hirsh J. Turpie AG, et al. CRC Crit Rev Clin Lab Sci. 1979;10(3):247-74. doi: 10.3109/10408367909147136. CRC Crit Rev Clin Lab Sci. 1979. PMID: 380902 Review.
The use of heparin in large doses to treat thrombosis is associated with hemorrhagic complications in up to 30% of patients. There is evidence that continuous i.v. heparin is associated with fewer hemorrhagic complications than intermittent i.v. heparin, but the fre …
The use of heparin in large doses to treat thrombosis is associated with hemorrhagic complications in up to 30% of patients. There is eviden …
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.
Rouet R, Thuma BA, Roy MD, Lintner NG, Rubitski DM, Finley JE, Wisniewska HM, Mendonsa R, Hirsh A, de Oñate L, Compte Barrón J, McLellan TJ, Bellenger J, Feng X, Varghese A, Chrunyk BA, Borzilleri K, Hesp KD, Zhou K, Ma N, Tu M, Dullea R, McClure KF, Wilson RC, Liras S, Mascitti V, Doudna JA. Rouet R, et al. J Am Chem Soc. 2018 May 30;140(21):6596-6603. doi: 10.1021/jacs.8b01551. Epub 2018 May 18. J Am Chem Soc. 2018. PMID: 29668265 Free PMC article.
82 results